Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

199 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer.
Prat A, Tsai YH, Pascual T, Paré L, Adamo B, Vidal M, Brasó-Maristany F, Galván P, Brase JC, Rodrik-Outmezguine V, Johnston S, Ciruelos E, Parker JS. Prat A, et al. Among authors: pascual t. Clin Cancer Res. 2020 Dec 1;26(23):6141-6148. doi: 10.1158/1078-0432.CCR-20-2793. Epub 2020 Sep 22. Clin Cancer Res. 2020. PMID: 32962980 Clinical Trial.
Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.
Fernandez-Martinez A, Pascual T, Perrone G, Morales S, de la Haba J, González-Rivera M, Galván P, Zalfa F, Amato M, Gonzalez L, Prats M, Rojo F, Manso L, Paré L, Alonso I, Albanell J, Vivancos A, González A, Matito J, González S, Fernandez P, Adamo B, Muñoz M, Viladot M, Font C, Aya F, Vidal M, Caballero R, Carrasco E, Altomare V, Tonini G, Prat A, Martin M. Fernandez-Martinez A, et al. Among authors: pascual t. Oncotarget. 2017 Mar 28;8(13):21930-21937. doi: 10.18632/oncotarget.15748. Oncotarget. 2017. PMID: 28423537 Free PMC article.
Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.
Prat A, Navarro A, Paré L, Reguart N, Galván P, Pascual T, Martínez A, Nuciforo P, Comerma L, Alos L, Pardo N, Cedrés S, Fan C, Parker JS, Gaba L, Victoria I, Viñolas N, Vivancos A, Arance A, Felip E. Prat A, et al. Among authors: pascual t. Cancer Res. 2017 Jul 1;77(13):3540-3550. doi: 10.1158/0008-5472.CAN-16-3556. Epub 2017 May 9. Cancer Res. 2017. PMID: 28487385
A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade.
Nuciforo P, Pascual T, Cortés J, Llombart-Cussac A, Fasani R, Paré L, Oliveira M, Galvan P, Martínez N, Bermejo B, Vidal M, Pernas S, López R, Muñoz M, Garau I, Manso L, Alarcón J, Martínez E, Rodrik-Outmezguine V, Brase JC, Villagrasa P, Prat A, Holgado E. Nuciforo P, et al. Among authors: pascual t. Ann Oncol. 2018 Jan 1;29(1):170-177. doi: 10.1093/annonc/mdx647. Ann Oncol. 2018. PMID: 29045543 Free article.
Intrinsic molecular subtypes of HER2+ breast cancer.
Prat A, Pascual T, Adamo B. Prat A, et al. Among authors: pascual t. Oncotarget. 2017 Sep 4;8(43):73362-73363. doi: 10.18632/oncotarget.20629. eCollection 2017 Sep 26. Oncotarget. 2017. PMID: 29088709 Free PMC article. No abstract available.
199 results